Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.360
-0.020 (-1.45%)
At close: Aug 6, 2026, 4:00 PM EDT
1.371
+0.011 (0.78%)
After-hours: Aug 6, 2026, 7:34 PM EDT
Vivani Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
42
Market Cap
117.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 3.38M | -3.52M | -51.00% |
| Dec 31, 2018 | 6.90M | -1.07M | -13.41% |
| Dec 31, 2017 | 7.96M | 3.98M | 99.85% |
| Dec 31, 2016 | 3.99M | -4.97M | -55.47% |
| Dec 31, 2015 | 8.95M | 5.55M | 163.39% |
| Dec 31, 2014 | 3.40M | 1.83M | 117.12% |
| Dec 31, 2013 | 1.57M | 197.78K | 14.47% |
| Dec 31, 2012 | 1.37M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Seer, Inc. | 15.17M |
| NRx Pharmaceuticals | 2.29M |
| Spruce Biosciences | 697.00K |
| Connect Biopharma Holdings | 233.00K |
| Genelux | 8.00K |
VANI News
- 12 hours ago - Vivani Medical announces full enrollment, initial dosing in SLIM-1 trial - TheFly
- 14 hours ago - Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - GlobeNewsWire
- 22 days ago - Vivani Medical Transcript: Emerging Growth Conference - Transcripts
- 23 days ago - Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026 - GlobeNewsWire
- 26 days ago - A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss - CNBC
- 4 weeks ago - Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139 - TheFly
- 4 weeks ago - Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - GlobeNewsWire
- 4 weeks ago - Vivani Medical Slides: Corporate presentation - Filings